Insilico Medicine and Eli Lilly inked a commercialization agreement for some of Insilico’s preclinical AI-discovered oral therapeutics, with economics tied to regulatory and commercial milestones. STAT+ reported the deal includes an $115 million upfront payment and potential value of about $2.75 billion in “biobucks,” positioning Lilly as a key partner for taking Insilico’s assets forward toward market.